LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 31

Search options

  1. Article: The Immunogenetics of Melanoma.

    Darbeheshti, Farzaneh

    Advances in experimental medicine and biology

    2022  Volume 1367, Page(s) 383–396

    Abstract: Melanoma is a relatively common and deadly type of skin cancer that originates from melanocytes. Cutaneous malignant melanoma results from the interplay between genetic susceptibility and environmental factors. Though the majority of melanoma cases are ... ...

    Abstract Melanoma is a relatively common and deadly type of skin cancer that originates from melanocytes. Cutaneous malignant melanoma results from the interplay between genetic susceptibility and environmental factors. Though the majority of melanoma cases are sporadic, several high and low penetrance mutations have been identified as underlying factors of heritable melanoma. Genetic variations in immune system components are among the most studied factors in melanoma heritability. They are involved in several aspects of the pathogenesis of the tumor including predisposition, cell proliferation, and apoptosis as well as immunotherapy. In this chapter, the hitherto available immunogenetic-related reports on melanoma predisposition and progression are summed up.
    MeSH term(s) Genetic Predisposition to Disease ; Humans ; Immunogenetics ; Melanocytes/pathology ; Melanoma/pathology ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology
    Language English
    Publishing date 2022-03-14
    Publishing country United States
    Document type Journal Article
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-3-030-92616-8_15
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies.

    Darbeheshti, Farzaneh / Makrigiorgos, G Mike

    International journal of molecular sciences

    2023  Volume 24, Issue 2

    Abstract: Low-level tumor somatic DNA mutations in tissue and liquid biopsies obtained from cancer patients can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up, or early cancer detection. Unless detected, such ... ...

    Abstract Low-level tumor somatic DNA mutations in tissue and liquid biopsies obtained from cancer patients can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up, or early cancer detection. Unless detected, such low-frequency DNA alterations can misinform patient management decisions or become missed opportunities for personalized medicine. Next-generation sequencing technologies and digital-PCR can resolve low-level mutations but require access to specialized instrumentation, time, and resources. Enzymatic-based approaches to detection of low-level mutations provide a simple, straightforward, and affordable alternative to enrich and detect such alterations and is broadly available to low-resource laboratory settings. This review summarizes the traditional uses of enzymatic mutation detection and describes the latest exciting developments, potential, and applications with specific reference to the field of liquid biopsy in cancer.
    MeSH term(s) Humans ; Neoplasms/diagnosis ; Neoplasms/genetics ; Liquid Biopsy/methods ; DNA, Neoplasm ; Mutation ; Polymerase Chain Reaction/methods ; High-Throughput Nucleotide Sequencing/methods ; Biomarkers, Tumor/genetics
    Chemical Substances DNA, Neoplasm ; Biomarkers, Tumor
    Language English
    Publishing date 2023-01-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24020923
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.

    Kouchaki, Hosein / Kamyab, Parnia / Darbeheshti, Farzaneh / Gharezade, Arezou / Fouladseresht, Hamed / Tabrizi, Reza

    Journal of the Egyptian National Cancer Institute

    2024  Volume 36, Issue 1, Page(s) 16

    Abstract: Background: MicroRNAs (miRNAs or miRs) are highly conserved non-coding RNAs with a short length (18-24 nucleotides) that directly bind to a complementary sequence within 3'-untranslated regions of their target mRNAs and regulate gene expression, post- ... ...

    Abstract Background: MicroRNAs (miRNAs or miRs) are highly conserved non-coding RNAs with a short length (18-24 nucleotides) that directly bind to a complementary sequence within 3'-untranslated regions of their target mRNAs and regulate gene expression, post-transcriptionally. They play crucial roles in diverse biological processes, including cell proliferation, apoptosis, and differentiation. In the context of cancer, miRNAs are key regulators of growth, angiogenesis, metastasis, and drug resistance.
    Main body: This review primarily focuses on miR-939 and its expanding roles and target genes in cancer pathogenesis. It compiles findings from various investigations. MiRNAs, due to their dysregulated expression in tumor environments, hold potential as cancer biomarkers. Several studies have highlighted the dysregulation of miR-939 expression in human cancers.
    Conclusion: Our study highlights the potential of miR-939 as a valuable target in cancer diagnosis, prognosis, and treatment. The aberrant expression of miR-939, along with other miRNAs, underscores their significance in advancing our understanding of cancer biology and their promise in personalized cancer care.
    MeSH term(s) Humans ; MicroRNAs/genetics ; Neoplasms/genetics ; Neoplasms/diagnosis ; Neoplasms/therapy ; Neoplasms/pathology ; Prognosis ; Gene Expression Regulation, Neoplastic ; Biomarkers, Tumor/genetics
    Chemical Substances MicroRNAs ; Biomarkers, Tumor
    Language English
    Publishing date 2024-04-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1176790-x
    ISSN 2589-0409 ; 1110-0362
    ISSN (online) 2589-0409
    ISSN 1110-0362
    DOI 10.1186/s43046-024-00220-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications.

    Darbeheshti, Farzaneh / Yu, Fangyan / Makrigiorgos, G Mike

    Cancers

    2022  Volume 14, Issue 13

    Abstract: Liquid biopsy is having a remarkable impact on healthcare- and disease-management in the context of personalized medicine. Circulating free DNA (cfDNA) is one of the most instructive liquid-biopsy-based biomarkers and harbors valuable information for ... ...

    Abstract Liquid biopsy is having a remarkable impact on healthcare- and disease-management in the context of personalized medicine. Circulating free DNA (cfDNA) is one of the most instructive liquid-biopsy-based biomarkers and harbors valuable information for diagnostic, predictive, and prognostic purposes. When it comes to cancer, circulating DNA from the tumor (ctDNA) has a wide range of applications, from early cancer detection to the early detection of relapse or drug resistance, and the tracking of the dynamic genomic make-up of tumor cells. However, the detection of ctDNA remains technically challenging, due, in part, to the low frequency of ctDNA among excessive circulating cfDNA originating from normal tissues. During the past three decades, mutation-enrichment methods have emerged to boost sensitivity and enable facile detection of low-level mutations. Although most developed techniques apply mutation enrichment during or following initial PCR, there are a few techniques that allow mutation selection prior to PCR, which provides advantages. Pre-PCR enrichment techniques can be directly applied to genomic DNA and diminish the influence of PCR errors that can take place during amplification. Moreover, they have the capability for high multiplexity and can be followed by established mutation detection and enrichment technologies without changes to their established procedures. The first approaches for pre-PCR enrichment were developed by employing restriction endonucleases directly on genomic DNA in the early 1990s. However, newly developed pre-PCR enrichment methods provide higher sensitivity and versatility. This review describes the available pre-PCR enrichment methods and focuses on the most recently developed techniques (NaME-PrO, UVME, and DEASH/MAESTRO), emphasizing their applications in liquid biopsies.
    Language English
    Publishing date 2022-06-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14133143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Prospect of exosomal circular RNAs in breast Cancer: presents and future.

    Zokaei, Elham / Darbeheshti, Farzaneh / Rezaei, Nima

    Molecular biology reports

    2022  Volume 49, Issue 7, Page(s) 6997–7011

    Abstract: Implementing precision oncology for breast cancer (BC) is a critical method for improving patient outcomes, which relies on the use of reliable biomarkers to be effective and safe. exosomes represent a potential alternative for the diagnosis and therapy ... ...

    Abstract Implementing precision oncology for breast cancer (BC) is a critical method for improving patient outcomes, which relies on the use of reliable biomarkers to be effective and safe. exosomes represent a potential alternative for the diagnosis and therapy of BC, As a "liquid biopsy" and a novel source for biomarkers. Exosomes are nanoscale phospholipid bilayer vesicles released by most cells that contain a large payload of various RNA species that can alter recipient cell activity. Circular RNAs (circRNAs) were recently revealed as a looping subclass of competing endogenous noncoding RNAs (ceRNAs) capable of microRNA sponging to regulate gene expression. They provide critical regulatory functions in carcinogenesis, proliferation, invasion, metastasis, and treatment resistance, as well as cancer prognostic. However, there is still a major gap in our understanding of the role of circRNA in the advancement of BC. CircRNAs are abundant in exosomes, according to various studies, and exosomal circRNAs (exo-circRNAs) play a significant role in cancer biology. Exo-circRNAs can be picked up by nearby or distant cells, affecting many features of the target cells' pathophysiological states, thus boosting cell communication and tumor spread. In this review, we have briefly summarized the major properties and functions of exosomes. Then, we have focused on exo-circRNAs, discussing their potential roles in both driving and inhibiting BC, as well as for cancer diagnosis, prognosis, and monitoring.
    MeSH term(s) Biomarkers ; Breast Neoplasms/genetics ; Female ; Humans ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Precision Medicine ; RNA, Circular/genetics
    Chemical Substances Biomarkers ; MicroRNAs ; RNA, Circular
    Language English
    Publishing date 2022-05-09
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-022-07472-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Genetic predisposition models to COVID-19 infection.

    Darbeheshti, Farzaneh / Rezaei, Nima

    Medical hypotheses

    2020  Volume 142, Page(s) 109818

    MeSH term(s) Adult ; Angiotensin-Converting Enzyme 2 ; Betacoronavirus/pathogenicity ; Betacoronavirus/physiology ; COVID-19 ; Child ; Coronavirus Infections/enzymology ; Coronavirus Infections/genetics ; Coronavirus Infections/virology ; Female ; Genes, X-Linked ; Genetic Predisposition to Disease ; Genetic Variation ; Host Microbial Interactions/genetics ; Host Microbial Interactions/physiology ; Humans ; Male ; Models, Genetic ; Pandemics ; Peptidyl-Dipeptidase A/genetics ; Pneumonia, Viral/enzymology ; Pneumonia, Viral/genetics ; Pneumonia, Viral/virology ; Receptors, Virus/genetics ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/physiology
    Chemical Substances Receptors, Virus ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Keywords covid19
    Language English
    Publishing date 2020-05-06
    Publishing country United States
    Document type Letter
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.

    Jalalvand, Mobina / Darbeheshti, Farzaneh / Rezaei, Nima

    Immunotherapy

    2021  Volume 13, Issue 7, Page(s) 587–603

    Abstract: Cancer initiation and progression are associated with immune system responses. Tumor cells use various tricks to scape of immune system, such as activating immune checkpoint pathways that induce immunosuppressive functions. Among the different immune ... ...

    Abstract Cancer initiation and progression are associated with immune system responses. Tumor cells use various tricks to scape of immune system, such as activating immune checkpoint pathways that induce immunosuppressive functions. Among the different immune checkpoint receptors, CTLA-4 and PD-1/PD-L1 are prominent therapeutic targets in different cancers. Although the US FDA has approved some immune checkpoint inhibitors for several cancers, concerning breast cancer still different clinical trials are looking for optimizing efficacy and decreasing immune-related adverse events. This review will discuss the existing body of knowledge with regard to cross-talk between immune system and tumor cells and then explore immune checkpoint-related signaling pathways in the context of breast tumors. Finally, we highlight the application of different immune checkpoint blockers in breast cancer patients.
    MeSH term(s) Breast Neoplasms/immunology ; Breast Neoplasms/therapy ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-03-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2495964-9
    ISSN 1750-7448 ; 1750-743X
    ISSN (online) 1750-7448
    ISSN 1750-743X
    DOI 10.2217/imt-2020-0283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Genetic predisposition models to COVID-19 infection

    Darbeheshti, Farzaneh / Rezaei, Nima

    Medical Hypotheses

    2020  Volume 142, Page(s) 109818

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109818
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Prospect of exosomal circular RNAs in breast Cancer: presents and future

    Zokaei, Elham / Darbeheshti, Farzaneh / Rezaei, Nima

    Molecular biology reports. 2022 July, v. 49, no. 7

    2022  

    Abstract: Implementing precision oncology for breast cancer (BC) is a critical method for improving patient outcomes, which relies on the use of reliable biomarkers to be effective and safe. exosomes represent a potential alternative for the diagnosis and therapy ... ...

    Abstract Implementing precision oncology for breast cancer (BC) is a critical method for improving patient outcomes, which relies on the use of reliable biomarkers to be effective and safe. exosomes represent a potential alternative for the diagnosis and therapy of BC, As a “liquid biopsy” and a novel source for biomarkers. Exosomes are nanoscale phospholipid bilayer vesicles released by most cells that contain a large payload of various RNA species that can alter recipient cell activity. Circular RNAs (circRNAs) were recently revealed as a looping subclass of competing endogenous noncoding RNAs (ceRNAs) capable of microRNA sponging to regulate gene expression. They provide critical regulatory functions in carcinogenesis, proliferation, invasion, metastasis, and treatment resistance, as well as cancer prognostic. However, there is still a major gap in our understanding of the role of circRNA in the advancement of BC. CircRNAs are abundant in exosomes, according to various studies, and exosomal circRNAs (exo-circRNAs) play a significant role in cancer biology. Exo-circRNAs can be picked up by nearby or distant cells, affecting many features of the target cells’ pathophysiological states, thus boosting cell communication and tumor spread. In this review, we have briefly summarized the major properties and functions of exosomes. Then, we have focused on exo-circRNAs, discussing their potential roles in both driving and inhibiting BC, as well as for cancer diagnosis, prognosis, and monitoring.
    Keywords biomarkers ; breast neoplasms ; carcinogenesis ; cell communication ; exosomes ; gene expression ; metastasis ; microRNA ; molecular biology ; patients ; phospholipids ; prognosis ; therapeutics
    Language English
    Dates of publication 2022-07
    Size p. 6997-7011.
    Publishing place Springer Netherlands
    Document type Article
    ZDB-ID 186544-4
    ISSN 1573-4978 ; 0301-4851
    ISSN (online) 1573-4978
    ISSN 0301-4851
    DOI 10.1007/s11033-022-07472-4
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top